Intellia Therapeutics, Inc.
- NTLA
- NASDAQ
- Biotechnology
- Genome Editing/CRISPR
- In Vivo Gene Therapy
$11.58
Today +1.40%Quote Oct 19, 2026, 08:00 PM UTC
−4.61%over the last month
Max drawdown −13.2%From 1-month high −11.4%3 months +1.0%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Intellia Therapeutics
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
377
Founded
2014
Market value
$1.62B
Quote Oct 19
Floor
$11.21
3.2% below price
Resistance
$11.85
2.4% above price
Price vs analyst targets
39 analysts
Lowest target
$8.00Highest target
$49.00
$8.00Highest target
$49.00
- Price $11.58
- Average target $21.64
- Analysts' target range
The price is close to the lowest analyst target. Analysts' average target sits about 87% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about NTLAPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free